Reaction

Bone Marrow Disorder reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,972 reports · 107 co-occurring drugs

As of the last recalculation, Bone Marrow Disorder appears in 2,972 FAERS reports alongside 107 co-occurring drug terms. The strongest observed disproportionality signal is ROMIPLOSTIM (PRR 25.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Romiplostim	54	25.6	25.7
Deferasirox	77	20.9	20.9
Venetoclax	139	16.5	16.6
Methadone Hydrochloride	24	15.7	15.7
Ruxolitinib	152	15.6	15.6
Azacitidine For	40	15.6	15.6
Standardized Senna Concentrate	25	14.0	14.1
Dalteparin Sodium	21	14.0	14.0
Azacitidine	58	13.9	14.0
Dasatinib	70	13.5	13.5
Doxorubicin Hydrochloride	61	13.3	13.4
Doxorubicin	150	12.4	12.4
Bendamustine Hcl	26	11.8	11.9
Posaconazole Delayed-Release	17	10.9	10.9
Niraparib	34	10.8	10.9
Polatuzumab Vedotin	15	10.8	10.8
Cytarabine	90	10.8	10.8
Filgrastim	54	10.2	10.2
Etoposide	103	10.1	10.1
Hydroxyurea	30	10.0	10.0
Posaconazole	23	10.0	10.0
Eculizumab	72	9.5	9.5
Carfilzomib	36	9.0	9.0
Ganciclovir Sodium	13	8.6	8.6
Erythropoietin	25	8.6	8.6
Cyclophosphamide Injection, Solution	201	8.5	8.5
Cyclophosphamide	201	8.5	8.5
Cyclophosphamide For Injection	201	8.5	8.5
Extended Phenytoin Sodium	20	8.4	8.4
Cisplatin	91	8.4	8.4
Ganciclovir	12	8.2	8.2
Fulvestrant	38	8.1	8.2
Eltrombopag Olamine	26	8.0	8.0
Rucaparib	10	8.0	8.0
Olaparib	23	7.8	7.8
Daptomycin	10	7.6	7.6
Bleomycin Sulfate	11	7.5	7.5
Imatinib Mesylate	29	7.3	7.4
Epoetin Alfa	12	7.1	7.1
Ribociclib	31	6.9	6.9
Melphalan	22	6.8	6.8
Vincristine Sulfate	28	6.7	6.8
Ifosfamide	20	6.6	6.6
Alemtuzumab	18	6.6	6.6
Melphalan Hydrochloride	23	6.5	6.5
Gentamicin	12	6.4	6.5
Axicabtagene Ciloleucel	9	6.4	6.4
Imatinib	16	6.4	6.4
Bosutinib	8	6.3	6.3
Gentamicin Sulfate	14	6.2	6.2
Mercaptopurine	14	5.7	5.7
Prochlorperazine Maleate	7	5.3	5.3
Letrozole	46	5.3	5.3
Letrozole Tablets	36	5.3	5.3
Nilotinib	22	5.3	5.3
Exemestane	16	5.3	5.3
Pegaspargase	9	5.2	5.2
Darbepoetin Alfa	39	5.1	5.1
Everolimus Tablets	12	5.0	5.0
Blinatumomab	7	4.7	4.7
Thalidomide	24	4.6	4.6
Fludarabine Phosphate	25	4.5	4.5
Gemcitabine	25	4.5	4.5
Interferon Beta-1B	12	4.4	4.4
Cladribine	6	4.4	4.4
Atovaquone	5	4.4	4.4
Mesna Injection	5	4.2	4.2
Acyclovir	67	4.2	4.2
Mesna	5	4.2	4.2
Ado-Trastuzumab Emtansine	5	4.2	4.2
Dexamethasone 1.5 Mg	166	4.1	4.1
Methadone	25	4.1	4.1
Dexamethasone	166	4.1	4.1
Daratumumab	23	4.1	4.1
Meropenem	18	3.9	3.9
Everolimus	28	3.9	3.9
Gemcitabine Hydrochloride	28	3.7	3.7
Iron Sucrose	5	3.7	3.7
Baricitinib	5	3.6	3.6
Ibrutinib	41	3.6	3.6
Abemaciclib	10	3.5	3.5
Bortezomib	44	3.5	3.5
Pemetrexed Disodium	18	3.3	3.3
Pemetrexed	10	3.3	3.3
Canakinumab	5	3.2	3.2
Voclosporin	4	3.2	3.2
Pomalidomide	46	3.2	3.2
Bendamustine Hydrochloride	5	2.9	2.9
Acalabrutinib	5	2.9	2.9
Peginterferon Alfa-2A	22	2.9	2.9
Bevacizumab	50	2.9	2.9
Carboplatin	51	2.8	2.8
Brentuximab Vedotin	4	2.7	2.7
Lenalidomide	158	2.7	2.7
Dofetilide	4	2.7	2.7
Paclitaxel (Aibumin-Bound)	31	2.7	2.7
Paclitaxel	37	2.6	2.6
Palbociclib	34	2.5	2.5
Durvalumab	7	2.4	2.4
Pegfilgrastim	33	2.4	2.4
Avapritinib	4	2.3	2.3
Lutetium Lu 177 Vipivotide Tetraxetan	4	2.1	2.1
Trifluridine And Tipiracil	3	2.0	2.0
Medroxyprogesterone Acetate	13	1.8	1.8
Ixazomib	7	1.7	1.7
Crizotinib	3	1.7	1.7
Voxelotor	3	0.9	0.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.